Urate Nephropathy Management

Diagnosis and Assessment

Renal function should be measured in all patients with hyperuricemia as part of standard assessment, according to the European League Against Rheumatism 1, 2

The European League Against Rheumatism recommends maintaining serum uric acid below 360 μmol/L (6 mg/dL) to promote crystal dissolution and prevent new crystal formation 2, 4
In patients with tophi, a more aggressive target of below 300 μmol/L (5 mg/dL) may be appropriate, as suggested by the European League Against Rheumatism 5
Allopurinol should be started at a low dose and gradually increased to achieve target serum urate levels, according to the European League Against Rheumatism 1, 4
Doses above 300 mg daily are often necessary to achieve target urate levels, as recommended by the European League Against Rheumatism 4
Febuxostat is an alternative for patients who cannot tolerate allopurinol or have renal impairment, according to the European League Against Rheumatism 1

In patients with mild-moderate renal impairment, allopurinol can be used with close monitoring, starting at 50-100 mg daily, as suggested by the European League Against Rheumatism 1, 4
Febuxostat and benzbromarone can be used without dose adjustment in renal impairment, according to the European League Against Rheumatism 1

Discontinuing urate-lowering therapy prematurely after achieving symptom control is a common pitfall to avoid, as warned by the European League Against Rheumatism 4
Relying solely on the standard 300 mg dose of allopurinol, which often fails to achieve target urate levels, is another pitfall to avoid, as noted by the European League Against Rheumatism 4
Underestimating the need for lifelong therapy based on temporary symptomatic improvement is a pitfall to avoid, as cautioned by the European League Against Rheumatism 4